CYP3A5 and epilepsy: Conversely, the CYP3A5*3 genotype did not affect the clearance of zonisamide, indicating that the CYP3A5*3 genotypes do not contribute significantly to the zonisamide pharmacokinetics in Japanese patients with epilepsy [12,129].